Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855882 | 1.00 | GPR3 (0.38) | GPR3HRH3L3MBTL1HTR2AHTR2C | |
| SCHEMBL29992908 | 1.00 | GPR3 (0.38) | GPR3HRH3L3MBTL1HTR2AHTR2C | |
| SCHEMBL21855883 | 1.00 | GPR3 (0.38) | GPR3HRH3L3MBTL1HTR2AHTR2C | |
| SCHEMBL22493738 | 1.00 | GPR3 (0.38) | GPR3HRH3L3MBTL1HTR2AHTR2C | |
| SCHEMBL21855951 | 0.89 | GPR3 (0.40) | GPR3L3MBTL1POLBLMNA | |
| SCHEMBL21855950 | 0.89 | GPR3 (0.40) | GPR3L3MBTL1POLBLMNA | |
| SCHEMBL24097165 | 0.87 | CHRM2 (0.39) | TSHR | |
| SCHEMBL22793052 | 0.87 | CHRM2 (0.39) | TSHR | |
| SCHEMBL22774338 | 0.87 | CHRM2 (0.39) | TSHR | |
| SCHEMBL21852133 | 0.87 | CHRM2 (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HRH3 4033/4885L3MBTL1 2686/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HRH3 4033/4885L3MBTL1 2686/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HRH3 4033/4885L3MBTL1 2686/4885 |
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | GPR3 3621/4885HRH3 4295/4885L3MBTL1 3514/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | GPR3 4426/4885HRH3 4033/4885L3MBTL1 2686/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | GPR3 3377/4885HRH3 3933/4885L3MBTL1 3727/4885 |
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN7 | GPR3 2009/4885HRH3 4439/4885L3MBTL1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.